The goal of this clinical trial is to find better protocal for adenocarcinoma of the gastric and gastroesophageal juncion.
The main question is aim to answer is:
1\. The efficacy and safety of PD-1 monoclonal antibody (Sintilimab) combined with nab-paclitaxel and S-1 in the first-line treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Participants will be given PD-1 monoclonal antibody, nab-paclitaxel and tegio.
Non resectable locally advanced, recurrent, or metastatic adenocarcinoma at the junction of the stomach and esophagus (including signet ring cell carcinoma, mucinous adenocarcinoma, and hepatoid adenocarcinoma) confirmed by histopathological examination.
Age ≥ 18 years old.
The ECOG PS score is 0 or 1.
The time from the end of previous (new) adjuvant chemotherapy/radiotherapy to disease recurrence is greater than 6 months.
Known signs of active bleeding in the lesion (excluding positive fecal occult blood).
Obstruction of the cardia and pylorus can affect the patient's eating and gastric emptying, or hinder the swallowing of medication.
Diagnosed as HER2 positive adenocarcinoma at the junction of the stomach and esophagus.
Previously received systematic treatment for advanced or metastatic adenocarcinoma at the junction of the stomach and esophagus.
Wu Jun
Lead sponsor
The First People's Hospital of Changzhou
Sponsor institution